Merck Kgaa

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$1.6Mgeneral payments (2019-2025)
$8,010research payments (2019-2025)
206clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $133K
2020 $99K
2021 $255K
2022 $465K
2023 $167K
2024 $286K
2025 $193K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Neurology (Psychiatry & Neurology) $696K
Medical Oncology $271K
Internal Medicine $236K
Hematology & Oncology $80K
Endocrinology, Diabetes & Metabolism $64K
Radiation Oncology $39K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Jeremy Sugarman Baltimore, MD Internal Medicine $151,947.40
Annette Okai Plano, TX Neurology (Psychiatry & Neurology) $61,833.59
Bruce Cree San Francisco, CA Neurology (Psychiatry & Neurology) $54,170.00
George Demetri Boston, MA Medical Oncology $49,647.03
Ravi Dukkipati York, PA Neurology (Psychiatry & Neurology) $46,285.43
Anthony Reder Burr Ridge, IL Neurology (Psychiatry & Neurology) $42,850.00
Ezra Cohen San Diego, CA Hematology & Oncology $40,609.92
Mitzi Williams Smyrna, GA Neurology (Psychiatry & Neurology) $38,573.58
Joaquin Bellmunt Molins Boston, MA Medical Oncology $36,015.38
Barry Hendin Phoenix, AZ Neurology (Psychiatry & Neurology) $34,949.23

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.